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in adults.2 Proton ‑pump inhibitors should only 
be used when appropriate, in accordance with la‑
bel instructions, and for the shortest duration to 
achieve symptom response, but several reports 
have described inappropriate prescription of PPIs 
both in primary care and hospital settings.1,3 Pro‑
longed PPI therapy is associated with adverse 
events and pharmacologic interactions.3,4,5 Un‑
desirable effects include small intestinal bacte‑
rial overgrowth, hypomagnesemia, decreased 
INTROduCTION Proton pump inhibitors (PPIs) 
are widely prescribed for treatment of acid ‑related 
gastrointestinal disorders such as peptic ulcer dis‑
ease, gastroesophageal reflux disease, or dyspep‑
sia. They also play a role in prevention of gastric 
ulcers in some clinical situations.1
The efficacy and perceived safety of PPIs have 
led to their widespread prescription and over‑
‑the ‑counter availability. In the United States, 
they are the most overprescribed medications 
ORIGINAL ARTICLE
Effect of long ‑term proton pump inhibitor 
therapy on complete blood count parameters 
and selected trace elements: a pilot study
Olga Kaczmarczyk1, Magdalena Przybylska ‑Feluś2,3, Agnieszka Piątek ‑Guziewicz2, 
Kacper Wcisło4, Mirosław Krośniak5, Jadwiga Kryczyk ‑Kozioł5, Krzysztof Kleszcz6, 
Paweł Zagrodzki5, Dorota Cibor2, Tomasz Mach2, Małgorzata Zwolińska ‑Wcisło2,3
1  Department of Gastroenterology and Hepatology, University Hospital, Kraków, Poland
2  Department of Gastroenterology, Hepatology and Infectious Diseases, Jagiellonian University Medical College, Kraków, Poland
3  Unit of Clinical Dietetics, Department of Gastroenterology, Hepatology and Infectious Diseases, Jagiellonian University Medical College, Kraków Poland
4  Students’ Scientific Association, Department of Gastroenterology, Hepatology and Infectious diseases, Jagiellonian University Medical College, Kraków, Poland
5  Department of Food Chemistry and Nutrition, Jagiellonian University Medical College, Kraków, Poland
6  State Higher Vocational School in Tarnów, Tarnów, Poland
Correspondence to:
Prof. Małgorzata Zwolińska ‑Wcisło, PhD, 
Clinical Dietetics Unit, Department 
of Gastroenterology, Hepatology and 
Infectious Diseases, Jagiellonian 
University Medical College, 
ul. Jakubowskiego 2, 30‑688 Kraków, 
Poland, phone: +48 12 400 31 50, 
email: mzwcislo@su.krakow.pl
Received: November 5, 2019.
Revision accepted: 
December 11, 2019.
Published online: December 11, 2019.
Pol Arch Intern Med. 2020; 
130 (3): 179‑186
doi:10.20452/pamw.15101
Copyright by Medycyna Praktyczna, 
Kraków 2020
KEy wORds
complete blood count, 
copper, proton pump 
inhibitors, selenium, 
zinc
AbsTRACT
INTROduCTION Proton pump inhibitors (PPIs) are widely prescribed for several gastrointestinal conditions, 
often as long ‑term therapy. The effects of long ‑term PPI use have not been fully elucidated.
ObjECTIvEs We aimed to determine the association between long ‑term PPI use and complete blood 
count parameters, particularly red blood cell (RBC) count, white blood cell (WBC) count, and hemoglo‑
bin concentrations, as well as serum levels of selected micronutrients such as selenium (Se), iron (Fe), 
copper (Cu), and zinc (Zn).
PATIENTs ANd mEThOds We enrolled 37 patients on long ‑term PPI therapy (mean [SD] age, 57.1 [15.4] 
years) and 30 healthy controls (mean [SD] age, 39.3 [11.8] years). In each group, complete blood count, 
and serum Fe levels were performed, and serum Cu, Zn, and Se levels were measured using atomic 
absorption spectrometry.
REsuLTs Red blood cell and WBC counts were lower in the PPI group compared with controls (mean 
[SD], 4.24 [0.55] ×106/μl vs 4.7 [0.4] ×106/μl; P <0.001 and 6.13 [1.44] ×103/μl vs 7.3 [1.28] ×103/μl; 
P <0.001, respectively). Hemoglobin and serum Fe concentrations were also lower in the PPI group (mean 
[SD], 12.5 [1.8] g/dl vs 14.3 [0.8] g/dl; P <0.001 and 16.3 [5.4] μmol/l vs 23.4 [2.7] μmol/l; P <0.001, 
respectively). Serum Zn and Cu concentrations were higher in PPI users than in controls.
CONCLusIONs Long ‑term PPI therapy may reduce RBC and WBC counts as well as hemoglobin levels, 
leading to iron deficiency. It may also affect concentrations of some micronutrients, although the underly‑
ing mechanism of this association is not fully clear.
EdITORIAL
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age of PPI users was 57.1 (15.4) years, and of con‑
trols, 39.3 (11.8) years. In the PPI group, 18 pa‑
tients used pantoprazole; 7, omeprazole; 1, lan‑
soprazole; 9, esomeprazole; and 2, dexlansopra‑
zole. Enrolled patients used the PPI due to gas‑
troesophageal reflux disease and functional dys‑
pepsia. The PPI ‑therapy duration varied between 
3 and 10 years at referral to Outpatient Gastro‑
enterology and Hepatology Clinic at Jagiellonian 
University Medical College in Kraków, Poland. Pe‑
riods without drug use did not exceed 3 months.
The exclusion criteria were as follows: pregnan‑
cy, any malignancies, diabetes mellitus, obesity 
(body mass index ≥30 kg/m2), cardiovascular dis‑
eases (hypertension, coronary artery disease, val‑
vular heart disease, cardiac arrhythmias), tobacco 
smoking, intake of medications that may affect se‑
rum Se, Zn, or Cu concentrations, as well as mal‑
absorption syndromes (eg, celiac disease, short 
bowel syndrome). Patients included in the study 
did not present overt or occult bleeding symp‑
toms. They did not take medications such as non‑
steroidal anti ‑inflammatory drugs, steroids, an‑
ticoagulant therapy, immunosuppressive, antivi‑
ral drugs, selective serotonin reuptake inhibitor 
treatment and chemotherapy.
biochemical analysis The biochemical analyses in‑
cluding complete blood count and the measure‑
ment of serum Fe concentrations were conducted 
at the Biochemical and Molecular Diagnostics Unit 
of the Department of Clinical Biochemistry at Ja‑
giellonian University Medical College, Kraków, Po‑
land. Complete blood count included the measure‑
ment of hemoglobin concentrations, mean corpus‑
cular volume (MCV), WBC, RBC, platelet count, 
and RBC distribution width (RDW).
The serum levels of Cu and Zn were mea‑
sured with the Perkin‑Elmer 5100ZL atomic ab‑
sorption spectrometer using flame technique 
(PerkinElmer Inc., Norwalk, Connecticut, Unit‑
ed States). The calibration curves for Cu and Zn 
were performed using 0, 0.25, 0.5, 1, 2, and 3 mg/l 
standards. These solutions were prepared by di‑
lution of standard solutions, 1000 mg/l (Merck, 
Darmstadt, Germany): Cu (1.19786.0 500) and 
Zn (1.19806.0 500). Thawed serum (0.5 ml) was 
mixed with 2 ml of demineralized water (Mil‑
li‑RQ10, Millipore, Vienna, Austria) and ana‑
lyzed as described above. Each sample was mea‑
sured 3 times. If the relative standard devia‑
tion of the 3 measurements exceeded 5%, then 
the sample was remeasured. The correctness of 
the obtained results was checked with Seronorm 
(200805) and Pathonorm (100705) control serum 
(Sero, Billingstad, Norway). The parameters for 
Cu were: wavelength, 324.8 nm; lamp current, 
15 mA; slit width, 0.7 nm; air flow, 9.0 l/min ; and 
acetylene, 2 l/min . The parameters for Zn were: 
wavelength, 213.9 nm; lamp current, 18 mA; slit 
width, 0.7 nm; air flow, 10.8 l/min ; and acety‑
lene 2 l/min .
The Se level was determined using the atom‑
ic absorption spectrometer Agilent Technologies 
cyanocobalamin absorption, acute interstitial 
nephritis, bone fractures, and diarrhea associat‑
ed with Clostridioides difficile (formerly Clostrid-
ium difficile).6 The use of PPI increases mortali‑
ty and hepatic decompensation in patients with 
liver cirrhosis.5 A correlation between PPI use 
and cognitive function has been postulated, but 
the exact effect seems to be unclear.7 A number 
of studies, discussed below, indicated a possible 
effect of changes in gastric acidity on the level of 
micronutrients, such as selenium (Se), zinc (Zn), 
and copper (Cu).
Selenium is an essential micronutrient that 
is incorporated in a variety of selenoproteins to 
render their beneficial physiologic functions. It 
also plays an important role as an antioxidant and 
is considered an anticancer nutrient.8 Steevens 
et al9 reported a negative correlation between 
the Se status and gastric and esophageal cancers.
Zinc is another micronutrient with a pivot‑
al role in homeostasis, immune function, oxida‑
tive reactions, apoptosis, and aging. It is a struc‑
tural element of Cu / Zn superoxide dismutase, 
which is intracellularly distributed in red blood 
cells (RBCs); therefore, it is involved in oxida‑
tive reactions. Zinc deficiency is related to sev‑
eral conditions such as malignancies, neuropsy‑
chiatric disorders, autoimmune diseases, or ag‑
ing processes with apoptosis.10
Copper is an essential trace element in human 
physiology and a major constituent of numerous 
enzymes. It is a potent antioxidant that plays 
an important role in the oxidant defense system.11 
Its deficiency results in microcytic anemia, leu‑
kopenia, and reduced bone density.12
The aim of this study was to determine the ef‑
fect of PPIs on complete blood count parameters, 
particularly RBCs, white blood cells (WBCs), and 
hemoglobin concentrations.
Moreover, we measured serum levels of Se, 
iron (Fe), Cu, and Zn in PPI users and compared 
with nonusers (controls).
PATIENTs ANd mEThOds study population A to‑
tal of 67 participants were enrolled to the study, 
including 37 PPI users (55%) and 30 healthy con‑
trols (45%) who did not use PPIs. The mean (SD) 
whAT’s NEw?
The study demonstrated that long ‑term proton pump inhibitor (PPI) therapy 
may reduce red blood cell count, white blood cell count, and hemoglobin lev‑
els, leading to iron deficiency. It may also affect the concentrations of some 
micronutrients such as copper and zinc, although the underlying mechanism 
of this association is not clear. We indicated that a change in gastric pH may 
not be the only factor affecting the intestinal absorption of trace elements in 
patients taking PPIs. Other such factor might be oxidative stress. On the other 
hand, gastroprotective effects of PPIs can not only be explained by their anti‑
secretory function. Our findings showed that PPIs should be prescribed with 
awareness. Monitoring of prolonged therapy should be introduced, particularly 
in the population of elderly or malnourished patients. This is especially important 
as PPIs are extensively prescribed both in primary care and hospital settings.
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The Levene test was used to assess the equality 
of variances in the study groups. A P value of less 
than 0.05 was considered significant. Pearson cor‑
relation coefficients were calculated for pairs of 
parameters. A partial least square (PLS) model 
was applied to describe the correlation structure 
between parameters in a mixed group of controls 
and patients treated with PPIs (using the analy‑
sis of component weights) and to reveal possible 
differences between controls and patients (using 
the analysis of PLS score plot). The PLS model 
showed the correlations between predictive pa‑
rameters such as age of patients, blood parame‑
ters, and concentrations of trace elements, with 
response parameters including Fe and hemoglo‑
bin concentrations (parameters characterizing 
oxygen binding and transport). Parameters with 
large weights (>0.3) in the PLS model were as‑
sumed to be correlated with one another. To ex‑
press the strength of bivariate associations, for 
the pairs of correlated parameters, the algebra‑
ic products of their corresponding weights and 
cosine of the corresponding angle were calculat‑
ed (these coefficients are called the correlation 
weights). The corresponding angle was defined 
as the angle determined by 2 lines connecting 
the origin with coordinates of both parameters 
on the PLS weights plot. The PLS approach was 
also applied with the aim to identify any possi‑
ble clusters of patients and healthy controls in 
the PLS score plot. Statistical analyses were car‑
ried out using the STATISTICA, version 12 pack‑
age (Statsoft, Tulsa, Oklahoma, United States) 
and SIMCA ‑P, version 9 (Umetrics, Umeå, Swe‑
den). The software delivered by MP System Sp. 
z o.o. (Chrzanów, Poland) was used to calculate 
correlation weights for the pairs of parameters in 
the PLS model and to detect outliers.
REsuLTs The comparison of analyzed parame‑
ters between the PPI and control groups is shown 
in TAbLE 1. Patients treated with PPIs had lower 
RBC and WBC counts as well as serum Fe levels 
than controls. The hemoglobin level was also low‑
er in patients treated with PPIs. There was no dif‑
ference in platelet counts between groups. Serum 
Zn and Cu levels were lower in controls than in 
the PPI group, but no differences were observed 
for Se levels. The Pearson correlation analysis 
showed positive correlations between RBC and 
hemoglobin levels, as well as RBC and serum Fe 
levels (TAbLE 2). An increase in the RBC count was 
correlated with higher hemoglobin concentra‑
tions and MCV. There was also a positive corre‑
lation between serum Se levels and MCV. No cor‑
relations between RBC and Cu or Se levels were 
observed (TAbLE 2).
Correlation weights obtained from the PLS 
model are presented in TAbLE 2. The final PLS 
model with 2 significant components, accord‑
ing to cross ‑validation, explained 50.6% of vari‑
ance in the predictive parameters, and 38.6% of 
variance in the response parameters, with eigen‑
values of 1.79 and 1.24 for the first and second 
240Z AA (Agilent Technologies, Santa Clara, Cal‑
ifornia, United States) with graphite furnace at‑
omization and Zeeman background correction. 
The calibration curve was prepared using 3 serum 
Se standards, namely, 0.35, 0.61, and 1.77 µmol/l . 
The accuracy of the results was confirmed with Se‑
ronorm reference material (Trace Elements Serum 
L ‑1, Sero). A hollow ‑cathode lamp with enhanced 
light intensity (“ultra ‑lamp”) (Agilent Technolo‑
gies, Santa Clara, Califormia, United States) was 
used as the light source, and high ‑purity argon 
(99.998%) (Linde Gaz Polska Sp. z o.o., Kraków, 
Poland) was used as inert gas.
Serum samples were mixed with 0.1% Triton 
solution (150 µl + 100 µl) to improve homoge‑
neity. Owing to the presence of complex organ‑
ic matrix in the samples, a chemical modifier 
was used and air ‑assisted ashing was included in 
the temperature program of the graphite furnace. 
The samples were measured in duplicates unless 
the obtained precision was not satisfactory (in 
such case samples were remeasured). The param‑
eters of the analysis were as follows: wavelength, 
196.0 nm; lamp current, 12 mA; slit, 1 nm; chem‑
ical modifier, 5% HNO3 containing 1500 mg/l
  Pd 
and 6000 mg/l  Mg(NO3)2; air ‑assisted ashing tem‑
perature, 400 °C; inert ‑gas ashing temperature, 
1150 °C; and atomization temperature, 2600 °C.
Ethical approval The study protocol was approved 
by the local bioethical committee at Jagiellonian 
University (no. KBET 122.6120.86.2015, as of 
May 28, 2015). All participants gave their writ‑
ten informed consent to be included in the study.
statistical analysis Data were expressed as mean 
(SD). The differences between groups were tested 
using the t test or the Welch test, as appropriate. 
TAbLE 1 Comparison of analyzed parameters between study groups
Parameter PPI (n = 37) Controls (n = 30) P value
Age, y 57.1 (15.4) 39.1 (11.8) <0.001
RBC, × 1012/μl 4.24 (0.55) 4.7 (0.4) <0.001
WBC, × 103/μl 6.13 (1.44) 7.3 (1.2) <0.001
Platelets, × 109/μl 259.1 (58.5) 263.3 (56) 0.77
Hemoglobin, g/dl 12.5 (1.8) 14.3 (0.8) <0.001
Fe, μmol/l 16.3 (5.4) 23.4 (2.7) <0.001
RDW ‑CV, % 13.1 (1.4) 13.6 (3.4) 0.45
RDW ‑SD, fl 41.0 (3) 40.8 (2.1) 0.08
MCV, fl 88.1 (5.6) 84.8 (3.3) <0.001
Zn, mg/l 0.95 (0.22) 0.83 (0.13) 0.01
Cu, mg/l 1.14 (0.25) 0.97 (0.22) <0.001
Se, μmol/l 0.98 (0.2) 0.93 (0.19) 0.33
Data are presented as mean (SD).
SI conversion factors: to convert WBC to × 109/l, multiply by 0.001; hemoglobin to g/dl, 
by 10; Zn to μmol/l, by 15.3; Cu to μmol/l, by 15.7.
Abbreviations: Cu, copper; Fe, iron; MCV, mean corpuscular volume; PPI, proton pump 
inhibitor; RBC, red blood cells; RDW ‑CV, red blood cell distribution width, coefficient of 
variation; RDW ‑SD, red blood cell distribution width, standard deviation; Se, selenium; 
WBC, white blood cells; Zn, zinc
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representing patients. True positive and nega‑
tive rates for this cluster were 86.7% and 87.8%, 
respectively. The separation between this clus‑
ter and patients was evident in the direction de‑
termined only by the first latent component of 
the PLS model. Considering this result, controls 
within this cluster were characterized by appar‑
ently higher RBC, WBC, hemoglobin, and Fe lev‑
els, as well as lower Cu levels and age compared 
with patients. This is in line with the results ob‑
tained by the t test or the Welch test (TAbLE 1).
dIsCussION The effect of prolonged PPI use on 
complete blood count has not been fully elucidat‑
ed so far. Our results revealed a relationship be‑
tween prolonged PPI use and reduced RBC and 
WBC counts as well as hemoglobin levels. One 
of the reasons for this finding may be reduced Fe 
levels demonstrated in patients treated with PPIs 
in comparison with controls, as reduced Fe levels 
may lead to subsequent changes in other parame‑
ters. In addition, we showed an effect of PPIs on 
serum concentrations of Cu and Zn.
Data on suppression of gastric acid during long‑
‑term PPI therapy leading to iron ‑deficiency ane‑
mia are sparse. Patients with Zollinger ‑Ellison 
syndrome during such therapy were shown to 
have reduced Fe levels.13 On the other hand, 
Hutchson et al14 showed reduced frequency of 
phlebotomy and absorption of nondietary Fe in 
patients with hereditary hemochromatosis on 
prolonged PPI therapy. In a retrospective cohort 
study, Sarzynski et al15 reported a decrease in he‑
moglobin, Ht, and MCV levels among patients on 
PPI therapy. Moreover, in a case ‑control study, 
Lam et al16 reported that a PPI use longer than 2 
years was associated with iron ‑deficiency anemia. 
In an open ‑labelled study, Qorray ‑Bytygi et al17 as‑
sessed ferritin levels at the beginning and after 12 
months of PPI therapy. They reported lower fer‑
ritin levels at 1 year in comparison with controls.
The presence of gastric acid facilitates dietary 
Fe absorption by dissociating Fe salts, increasing 
solubility, and transforming them to the ferrous 
form.18 The above observations are consistent 
components, respectively. Five predictive param‑
eters (age, Cu, Se, MCV, and WBC) and 2 response 
parameters (Fe, hemoglobin) were included in 
the PLS model, while others were excluded as 
they were considered noninformative (FIGuRE 1). 
The first latent component in this model had pos‑
itive weights predominantly for the RBC count, as 
well as for hemoglobin and Fe levels, while it had 
high negative weight for age. The highest positive 
correlation weights based on this latent compo‑
nent were revealed between RBC count and both 
hemoglobin and Fe levels. The second latent com‑
ponent was loaded again mainly by RBC count, 
and 4 other parameters with similar weights: he‑
moglobin, Se, MCV, and Cu. Therefore, RBC count 
had high correlation weights with all these param‑
eters. The PLS model revealed correlation struc‑
ture between the above parameters: RBC and he‑
moglobin, RBC and Fe, Se, and MCV, and also be‑
tween RBC and Se, RBC and Cu, age and hemo‑
globin, as well as age and RBC. For the correla‑
tion between RBC count and MCV, we obtained 
discrepant results using the PLS model and Pear‑
son correlation analysis.
The results of patients determined by the first 
2 latent components are shown in FIGuRE 2. A rel‑
atively tight cluster of squares representing con‑
trols can be distinguished among the cloud of dots 
TAbLE 2 Correlation weights based on the partial least square model (only correlation 
weights with absolute values higher than 0.15 are shown)
Pairs of correlated 
parameters
Correlation 
weights
Pearson correlation 
coefficients
P value
RBC with hemoglobin 0.396 0.712 0.001
RBC with MCV 0.279 –0.331 0.01
RBC with Cu 0.254 0.001 0.99
RBC with Se 0.242 0.081 0.51
RBC with Fe 0.203 0.295 0.01
Se with MCV 0.156 0.325 0.01
Age with hemoglobin –0.201 0.220 0.07
Age with RBC –0.319 –0.210 0.08
Abbreviations: see TAbLE 1
FIGuRE 1 The weights 
of the first 2 components 
of the partial least square 
model 
Abbreviations: 
Hb, hemoglobin; others, 
see TAbLE 1
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tried to eliminate the influence of the age differ‑
ence of the studied groups on the results of mea‑
sured parameters by using the PLS model.
In contrast to the RBC count, platelet counts 
did not differ between groups. Literature data 
concerning platelet count are conflicting. Only 
a few case reports and one retrospective study 
described PPI ‑induced thrombocytopenia.19-22
To the best of our knowledge, there have been 
no studies analyzing the WBC count during PPI 
therapy. Neutropenia and agranulocytosis are rare 
adverse effects associated with PPI treatment. So 
far, only a few case reports of severe neutropenia 
or agranulocytosis during PPI use (ie, omepra‑
zole) have been published.23-25
The suggested pathomechanisms of neutro‑
penia includes immune reactions and cross‑
‑reactivity. Also, synergic reactions with other 
potential causes of neutropenia should be con‑
sidered. In our study, we observed a significantly 
lower WBC count in patients on PPI therapy than 
in controls, and only 2 patients had slight leuko‑
penia. Further studies in patients on PPI thera‑
py, with careful monitoring of WBC and its sub‑
populations, are needed.
It has been shown that gastric acid is required 
for the release of vitamin B12 from food; therefore, 
PPIs are believed to cause vitamin B12 deficiency. 
In our study, we did not measure serum vitamin 
B12 concentrations. However, in a cross ‑sectional 
study, den Elzen et al26 reported that long ‑term 
PPI use was not associated with vitamin B12 de‑
ficiency. On the other hand, Qorraj ‑Bytyqi et al17 
reported a change in serum cyanocobalamin con‑
centrations at 1 year of PPI therapy.
To the best of our knowledge, there are no lit‑
erature data on changes in MCV during PPI ther‑
apy. Despite differences in Fe levels between pa‑
tients on PPI therapy and controls, we did not ob‑
serve any differences in MCV. This finding can be 
explained by the multifactorial effect of various 
parameters on the size of erythrocytes. The val‑
ues of MCV may be affected by Fe deficiency and 
vitamin B12 deficiency. An interesting observation 
with the results of our studies indicating de‑
creased RBC count as well as hemoglobin and Fe 
levels in PPI users.
The PLS model revealed correlation structure 
between the majority of analyzed parameters. 
The RBC count was strongly correlated with all 
parameters except the WBC count. The biochem‑
ical basis for the observed correlations between 
RBC and hemoglobin, Fe, and Cu can be easily ex‑
plained, because Fe and Cu play a fundamental 
role in erythropoiesis, and hemoglobin is an es‑
sential constituent of RBCs. The negative cor‑
relation of age with RBC and hemoglobin may 
be explained by the fact that lower RBC count 
and hemoglobin levels were observed in patients 
who were, at the same time, older than controls. 
The question of whether this was an accidental 
finding or whether it occurred in the course of 
the disease or due to the disease itself needs to 
be addressed in future studies.
The distinct cluster of squares representing 
controls (containing only a  few patients) on 
the plane defined by the first 2 latent compo‑
nents of the PLS model reflects a notable differ‑
ence in biochemical characteristics between pa‑
tients and controls, which means that the PLS 
model is effective enough to differentiate between 
these 2 groups. Our analysis indicated that RBC, 
hemoglobin, and age were the parameters that 
differed the most between patients and controls. 
To the best of our knowledge, no clinical trials on 
patients taking PPIs have used the PLS approach 
to interpret the results.
A drawback of this study is a relatively small 
number of the patients studied and quite a large 
difference in mean age between the control and 
treatment groups. To exclude additional effects 
on blood test and Fe values, included patients did 
not present overt or occult bleeding symptoms. 
The study group, despite being older than the con‑
trol group, did not have more serious, chronic dis‑
eases that could affect the parameters tested, did 
not take medications such as nonsteroidal anti‑
‑inflammatory drugs, steroids, clopidogrel. We 
FIGuRE 2  
The projection of patients 
and controls on the plane 
defined by the first 
2 latent components of 
the partial least square 
model. The elliptical 
shape represents 
the cluster of controls.
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Selenium plays a major role in redox reactions 
and controls cell ‑mediated immunity.41 Selenopro‑
teins determine a protective mechanism against 
reactive oxygen and nitrogen species. High lev‑
els of this micronutrient may have a negative ef‑
fect on carcinogenesis.42 Nezhad et al43 reported 
higher Se levels in patients with functional dys‑
pepsia in comparison with those with gastric can‑
cer. Ustundag et al44 reported that Se collected in 
gastric tissue in patients with Helicobacter pylo-
ri–related antral inflammation and then its lev‑
els decreased after effective H. pylori eradication. 
Wu et al45 also reported a reduction in serum Se 
levels after H. pylori eradication. To our knowl‑
edge, there are currently no reports of the PPI 
impact on Se status. The changes of microbio‑
ta in the small intestine because of prolonged 
PPI treatment may play an important role in the 
regulation of serum Se levels, because it is most‑
ly absorbed in the duodenum and cecum by ac‑
tive transport through a sodium pump.46 Despite 
this, we found no difference in Se concentrations 
between our groups.
Proton ‑pump inhibitors may interact with oth‑
er drugs by reducing gastric acidity, modifying 
metabolism (generally through the cytochrome 
P450 enzyme system), or inhibiting extragastric 
renal proton pumps.47 In order to exclude these 
potential interactions, patients with serious con‑
comitant conditions requiring use of immuno‑
suppressive, antiviral, selective serotonin reup‑
take inhibitor treatment or chemotherapy were 
excluded from the study.
It is understood that short‑time use of over‑
‑the ‑counter PPIs does not have any deleterious 
effect on the absorption of micronutrients such as 
Fe, calcium, magnesium, and vitamin B12
47; how‑
ever, prescription PPIs in our study were gener‑
ally administered at higher doses and the dura‑
tions of treatment were longer.
Our results may indicate that the concentra‑
tions of micronutrients such as Zn, Se, or Cu in pa‑
tients taking PPIs are not only dependent on their 
absorption potentially impaired due to the re‑
duction of gastric acidity. We hypothesize that 
their concentrations can be affected also by oth‑
er factors, such as oxidative stress. All the above 
trace elements are potent antioxidants involved 
in the oxidant defense system. On the other hand, 
gastroprotective effects of PPIs cannot only be 
explained by their antisecretory function. Re‑
cent studies have shown a more direct effect of 
omeprazole on the integrity of gastric muco‑
sa, including antiapoptotic, anti ‑inflammatory, 
and free radical scavenging functions.48 Because 
the emerging evidence indicates an involvement 
of reactive oxygen species in the pathomechanism 
of gastric lesions,48 the antioxidant actions of PPIs 
might produce the noted acid ‑independent gas‑
troprotective effects. Becker et al49 demonstrat‑
ed that heme oxygenase ‑1 is an antioxidant me‑
diator of PPIs in gastric epithelial cells as well as 
vascular endothelial cells. High ‑dose PPIs have 
shown promise as chemopreventive agents for 
is the positive correlation between Se levels and 
MCV, as well as the surprising lack of differences 
in these parameters between study groups. This 
relationship requires further research. The high 
concentration of Se in RBCs (higher than in most 
other blood fractions or whole blood),27 high ac‑
tivity of selenoenzyme glutathione peroxidase28 
as well as Se transfer to and from hemoglobin29 
have been already reported by various authors. 
However, the molecular mechanisms behind 
the positive correlation between plasma Se lev‑
els and RBC count remain to be fully clarified. Of 
note, Wasowicz and Zachara30 found a correla‑
tion between Se levels in erythrocytes and whole 
blood (r = 0.879; P <0.001).
Hypochlorhydria may contribute to decreased 
calcium and magnesium absorption and could 
have the same effect on other cations, such as Zn.1 
It should be noted that plasma Zn levels are not 
affected by mild changes in dietary Zn, and only 
a significant and prolonged reduction of Zn intake 
leads to a notable deficiency.31 One study report‑
ed inhibited absorption of Zn during PPI thera‑
py.32 On the other hand, Turnbull et al33 indicat‑
ed that low gastric pH may not be necessary for 
intestinal absorption of Zn. Serfaty ‑Lacrosniere 
et al34 did not find a difference in intestinal Zn 
absorption between omeprazole ‑treated patients 
and controls. These observations seem to be in 
line with our results. Surprisingly, we showed 
higher serum Zn concentrations in PPI ‑treated 
group than in controls. Moreover, Ergul et al35 
showed a negative correlation between vitamin 
B12 levels and Zn deficiency. This suggests that 
Zn absorption may be a more complex issue than 
it has been considered so far. Importantly, Kir‑
choff et al36 indicated that Zn results in a rapid 
and prolonged reduction of gastric acid produc‑
tion. Perhaps the observed increase in Zn con‑
centrations in the PPI group may be a manifes‑
tation of defense mechanisms in conditions as‑
sociated with hypersecretion of acid regardless 
of PPI treatment.
The adverse consequence of Zn excess is Cu de‑
pletion.32 A reduction in the Cu level may lead to 
anemia, nerve damage, and bone loss.37 There are 
scarce and conflicting data on the effects of PPIs 
on Cu levels. Plantone et al38 hypothesized that 
a chronic and prolonged reduction of gastric acid‑
ity may reduce Cu absorption. Joshaghani et al39 
showed no difference in serum Cu concentrations 
after 8 weeks of omeprazole use. On the other 
hand, Ece et al40 found that while hemoglobin val‑
ues of children with iron ‑deficiency anemia were 
decreasing, their serum Cu concentrations were 
increasing. Thus, an increase in Cu absorption oc‑
curs with increasing Fe deficiency. This is in line 
with our observations. Patients on PPI therapy in 
our study showed higher serum Cu levels and low‑
er Fe levels in comparison with controls. Moreover, 
Cu and Zn levels in the PPI group were higher than 
in controls. This may indicate that a change in gas‑
tric pH may not be the only factor affecting the in‑
testinal absorption of trace elements.
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esophageal adenocarcinoma in Barrett esopha‑
gus fitting with the hypothesis that this cancer is 
an inflammatory ‑mediated malignant response 
to prolonged acid exposure.50 The involvement 
of Zn, Se, and Cu in a potential antioxidant re‑
action induced by PPIs requires further research.
Conclusions Our findings show that PPIs should 
be prescribed with caution and awareness. Pro‑
longed PPI use affects complete blood count, 
in particular RBCs and WBCs. Moreover, PPIs 
cause changes in iron absorption, with subsequent 
changes in RBC count and hemoglobin levels.
Monitoring of prolonged therapy should be in‑
troduced, particularly in the population of elder‑
ly or malnourished patients. Inappropriate PPI 
use may result in significant adverse effects and 
potential interactions. Awareness of evidence‑
‑based guidelines and targeted medicine prescrip‑
tion strategies are essential for cost ‑effective and 
safe use of this drug class. Patients overusing PPIs 
should be screened and properly educated about 
guideline recommendations and indications for 
prescription.
The concentrations of some micronutrients 
may change as a  result of PPI use, although 
the mechanism of this phenomenon is com‑
plex and not fully clear. The antioxidant func‑
tions of PPIs might account for the noted acid‑
‑independent gastroprotective effects. The in‑
volvement of Zn, Se, and Cu in a potential anti‑
oxidant reaction induced by a PPI requires further 
research. Comparative studies on the concen‑
trations of these micronutrients before and af‑
ter the PPI therapy are needed. Further studies 
with higher number of enrolled patients with 
a uniform distribution of age between the groups 
to support our preliminary observations are 
necessary.
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